Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by BearDownAZon Oct 16, 2015 1:24pm
116 Views
Post# 24198710

RE:RE:RE:RE:RE:RE:Unfortunate timing - Nicholls article on RVX - 09/15

RE:RE:RE:RE:RE:RE:Unfortunate timing - Nicholls article on RVX - 09/15One correction to my previous (and long) post. I originally wrote: "The 2 events (2 deaths) in the diabetic placebo group of 168 patients equates to a 3.077% event rate. The 1 event (1 MI) iin the diabetic RVX-208 group of 331 patients equates to a 0.7874% event rate. This is a 0.2559 hazard ratio for a RRR of ~74.4%." 

It should have read "The 2 events (2 deaths) in the diabetic placebo group of 65 patients equates to a 3.077% event rate. The 1 event (1 MI) iin the diabetic RVX-208 group of 127 patients equates to a 0.7874% event rate. This is a 0.2559 hazard ratio for a RRR of ~74.4%."

Best,

BDAZ
Bullboard Posts